Lung cancer / Breast cancer / Lymphoma / Head and neck cancer / Endometrial cancer / Colorectal cancer

Clinical research patient recruitment

If you initially meet the enrollment criteria, the center will provide free one-on-one consultation services with an oncology specialist.
Sign up now

ongoing research

Recruiting Clinical Trials

What is clinical research?

There are two types of medical research on cancer treatment drugs:

Category 1:
Preclinical trials involve testing the drug on cancer cells cultured in animals or laboratories to observe whether it has a preliminary inhibitory effect on cancer cells.

Category 2:
Clinical trials involve studying drugs on humans. Clinical trials are divided into several stages:

  1. The safety of the drug was tested on healthy individuals.
  2. We are attempting to achieve initial success among relevant patients.
  3. The extent to which the benefits of the treatment are confirmed is usually quite significant.
  4. After a drug has been on the market for some time, data on its therapeutic efficacy and side effects are collected to confirm whether the treatment effect in a real-world setting is as shown in the research data, and to rule out the possibility of the drug causing extremely rare side effects.

If your doctor recommends that you participate in a clinical trial, it means that your tumor characteristics meet the initial screening requirements of a certain clinical trial. The process usually involves blood tests, imaging examinations, and electrocardiograms to confirm that the functions of various organs are generally normal and whether specific inclusion requirements are met, such as no brain metastases, measurable tumors larger than 1 cm (which can accurately measure size and objectively judge drug efficacy), etc.

If you are invited to participate in a study, you should first approach it with a calm mindset and try to understand the background, purpose, and process of the study, as well as the expected benefits and potential side effects of the investigational drug used.

Sign up now
【患者招募】 轉移性乳腺癌_CHI@3x-100
【患者招募】完成腫瘤切除手術, ctDNA 陽性或具有高風險病理特徵的 I 期非小細胞肺癌的患者_CHI @3x-100
晚期或轉移性乳癌
不可切除、局部晚期或轉移性非小細胞肺癌

Doctors typically recommend that
articipate in clinical trials for several reasons.

It is believed that the drug under investigation is better than all current treatment options.
Patients are unable to afford standard treatments or medications due to financial reasons.
It is hoped that patients who participate in the study will receive free treatment.

Regardless of the reason mentioned above, doctors always act in the patient's best interest,
hoping for better control of the patient's condition.

No matter which of the above reasons
Doctors are all for the benefit of the patient
Hope the patient's condition
Get better control

Clinical trials must undergo rigorous review by a medical ethics committee. Approval is only granted if the potential benefits outweigh the risks and the trials are deemed suitable for patient testing. Most studies are covered by substantial medical insurance to protect patients against rare but serious drug side effects or procedural errors that could lead to long-term complications, providing patients with an extra layer of protection.

Currently, most clinical trials in Hong Kong are in phase II and III, with very high safety profiles. In randomized controlled trials, patients will receive appropriate basic treatment regardless of which drug they are assigned, along with free CT scans, MRI scans, and blood tests, effectively saving patients significant medical expenses. Therefore, if invited to participate in a study, please be open-minded, understand the doctor's reasons for recommending participation, and carefully consider the doctor's advice to develop the best treatment plan for your condition!

Sign up now

Participation in clinical research process

參與臨床研究流程​

1.Contact us

Contact us by phone or WhatsApp to reach the Hong Kong United Cancer Centre. Patients should provide their medical records to a specialist for initial assessment of their eligibility for research. Eligible patients will be arranged for a free consultation with an oncology specialist.

2. Doctors' consultation

The doctor will further assess whether the patient meets the eligibility criteria for participation in the study and explain the process and risks involved. If the patient wishes to participate in the study, they must sign a consent form.

3. Screening Phase

Research staff will arrange the following tests for patients to confirm their eligibility for the study.
• Gene protein testing (depending on research requirements)
• Blood tests and imaging examinations

4. Notification of Results

Within 28 days of the doctor's appointment, research staff will contact the patient or their family to inform them of the results. Patients approved for the study can immediately begin treatment.

5. Arrange treatment

Research staff will schedule treatment times for patients.
Patients need to follow the research guidelines and undergo routine check-ups at the cancer center:
• Blood tests will be performed during each treatment session.
• Imaging examinations every 6/9 weeks
(The number of related examinations may vary depending on individual study guidelines.)

Fee arrangement:
• All examinations and research-related medications performed during the research process are covered free of charge.
• If the patient's condition subsequently worsens, additional treatment costs will be required.

If you initially meet the enrollment criteria,
the center provides free one-on-one consultation services with oncology specialists.

Sign up now

Study recruitment subjects

The Hong Kong United Cancer Centre is currently conducting several international clinical studies. If you are:

Lung cancer
  • Newly diagnosed Non-Small Cell Lung Cancer (NSCLC)
  • Newly diagnosed NSCLC with high PD-L1 expression in tumor cells
  • Newly diagnosed NSCLC with EGFR gene mutation
  • Newly diagnosed NSCLC with HER2 gene mutation
  • NSCLC with KRAS gene mutation
  • Surgically resectable NSCLC
breast cancer
  • HER2-low expression, hormone receptor-positive metastatic breast cancer
  • Metastatic breast cancer currently receiving hormone and CDK4/6 inhibitor therapy
  • Triple-negative breast cancer that has received preoperative adjuvant therapy

Please call our cancer center as soon as possible for further follow-up. Those interested can contact us through the following methods

Whatsapp：5518 2992      
Email: Enquiry@hkuoc.hk  

Sign up now

Clinical research physician team

Dr. Li Yu Chung, Jacky
Clinical Oncology Specialist

Bachelor of Medicine and Surgeon General Practice (MBBS) from the University of Hong Kong
Fellow of The Royal College of Radiologists (UK) FRCR (UK)
Fellow of the Hong Kong College of Radiologists FHKCR
Fellow of the Hong Kong Academy of Medicine (Radiology) FHKAM (Radiology)

Dr. Wu Jianbang
Internal Medicine and Oncology Specialist

Licentiate of the Medical Council of Hong Kong LMCHK
Postgraduate Diploma in Community Geriatric Care, The University of Hong Kong P DipCG (Hong Kong)
Postgraduate Diploma in Infectious Diseases, The University of Hong Kong P DipID (HK)
Membership of the Royal Colleges of Physicians (UK) MRCP (UK)
Fellow of the Hong Kong Academy of Medicine (Medicine) FHKAM (Medicine)
Postgraduate Diploma in Clinical Dermatology, University of London PGDipClinDerm (Lond)

Dr. Tang Yingxin
Internal Medicine and Oncology Specialist

Bachelor of Medicine and Surgeon General Practice (MBBS) from the University of Hong Kong
Membership of the Royal Colleges of Physicians (UK) MRCP (UK)
Fellow of the Hong Kong College of Physicians FHKCP
Fellow of the Hong Kong Academy of Medicine (Medicine) FHKAM (Medicine)
Postgraduate Diploma in Infectious Diseases, The University of Hong Kong P DipID (HK)

Research drugs completed

Completed Clinical Trial

Clinical Trial Enrollment - Application

WhatsApp Facebook WeChat Weibo